This site is intended for Great Britain healthcare professionals only 

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety Guidance
DosingDosingDosingOral once-daily dosingPractical ConsiderationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
Materials

Information on how to access Cibinqo® (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

JADE clinical trial programme​​​​AnchorCibinqo has been studied across six Phase III trials as monotherapy or in combination with medicated topical therapies1–7JADE COMPARE1,2
16-week study
Cibinqo in combination with medicated topical therapy in patients aged ≥18 years• Evaluated skin clearance and itch relief vs placebo at Week 12 (co-primary endpoint) and Week 16
• Dupilumab* as active comparator to evaluate skin clearance and itch relief
• Superiority examined vs dupilumab for itch relief at Week 2
View trial informationLoading
JADE MONO-1 and MONO-21,3,4
12-week study
Cibinqo as monotherapy in adults and adolescents ≥12 years• Evaluated skin clearance and itch relief vs placebo at Week 12View trial informationLoading
JADE REGIMEN1,5
52-week study

Cibinqo treatment durability in adults and adolescents ≥12 years:

• Durability of treatment response
• Risk of flaring following change from Cibinqo 200 mg to either 200 mg, 100 mg or placebo
• Studied across induction, maintenance, dose reduction, withdrawal and rescue therapy strategies

View trial informationLoading
JADE TEEN​​​​​​​1,6
12-week study

Cibinqo in combination with medicated topical therapy in patients 12–17 years

• Evaluated skin clearance and itch at Week 12
• Evaluated safety in adolescent population

View trial informationLoading
JADE EXTEND​​​​​​​1,7
Ongoing long-term study

Long-term safety and efficacy of Cibinqo in adults and adolescents aged ≥12 years

• Primary objective is to evaluate the long-term safety of Cibinqo
​​​​​​​• Secondary objective to estimate the long-term efficacy of Cibinqo, including skin clearance and itch relief

View trial informationLoading
JADE efficacy endpointsEfficacy assessments for Cibinqo in the clinical trial programmePrimary and key secondary endpoints
Scroll left to view table
Header Assessment
Endpoint
Eczema Area and Severity Index (EASI)8
 EASI is a composite scoring of the degree of erythema, induration/papulation, excoriation and lichenification (scored separately) for each of four body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body.
EASI score:
0 = no symptoms
72 = greatest severity
EASI excluded scalp, palms and soles from the assessment/scoring.

 
Co-primary endpoints​​​​​​​
Investigator's Global Assessment (IGA)9

A 5-point scale (0–4) reflecting a global consideration of the erythema, induration and scaling, giving an overall severity of AD.

IGA excluded scalp, palms and soles from the assessment/scoring.
Peak Pruritus Numerical Rating Scale (PP-NRS)10
 
Patients keep a daily diary of itch severity, recording their worst itching due to AD over the past 24 hours.
0 = no itch
10 = worst possible itch imaginable
 
Key secondary endpoint
Other secondary endpoints
Scroll left to view table

Assessment Endpoint
Patient-Oriented Eczema Measure (POEM)2 POEM is a validated 7-item patient-reported outcome measure used to assess the impact of AD recalled over the past week. It is used to evaluate and measure itch, sleep disturbance, bleeding skin, weeping/oozing skin, cracked skin, flaking skin and dry/rough skin, from the patient’s perspective.

Scores range from 0–28, with higher scores indicating greater severity.


Secondary endpoint
SCORing Atopic Dermatitis (SCORAD)2  
SCORAD is a validated scoring index for AD, which combines extent (taking into account BSA affected by AD), severity, and subjective symptoms based on itch and sleep loss.

​​​​​​​Scores range from 0–103 with higher scores indicating greater severity.
 
Secondary endpoint
Dermatology Life Quality Index (DLQI)2  
 
DLQI is a validated general dermatology questionnaire that consists of 10 items to assess subject-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).

​​​​​​​Scores range from 0–30, with higher scores indicating greater impact on quality of life.

 
Secondary endpoint
Before/After patient imagesImprovement in skin clearance: Patients at Week 12, across skin tones, with or without Rx topicals.Please note that the following are examples. Patient response to treatment will vary.GalleryAnchor
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 1

GENDER: Male
TRIAL: JADE MONO-2
​​​​​​​DOSAGE: Cibinqo 100 mg
AGE: 24
MEDICATED TOPICALS: No

BASELINE

AT WEEK 12

Patient 2

GENDER: Female
TRIAL: JADE MONO-2
DOSAGE: Cibinqo 200 mg
AGE: 40
MEDICATED TOPICALS: No

BASELINE

AT WEEK 12

Patient 3

GENDER: Male
TRIAL: JADE MONO-2
​​​​​​​DOSAGE: Cibinqo 200 mg
AGE: 22
MEDICATED TOPICALS: No

BASELINE

AT WEEK 12

Patient 4

GENDER: Male
TRIAL: JADE COMPARE 
DOSAGE: Cibinqo 200 mg
AGE: 21
MEDICATED TOPICALS: Yes

BASELINE

AT WEEK 12

Patient 5

GENDER: Female
TRIAL: JADE MONO-2 
DOSAGE: Cibinqo 100 mg
AGE: 28
MEDICATED TOPICALS: No

BASELINE

AT WEEK 12

Explore moreSafety

3,128 patients were treated with Cibinqo in clinical studies in AD representing 2,089 patient-years of exposure.1

View safety guidanceLoading
  • References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.

Dosing

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosingLoading
*Dupilumab was an active comparator in JADE COMPARE. Comparisons between the dupilumab group and other trial groups were not multiplicity-controlled, except with respect to itch response at Week 2.

​​​​​​​Images of patients from Cibinqo clinical trials. Not everyone will respond to treatment with Cibinqo. Individual results may vary.

​​​​​​​AD=atopic dermatitis; BSA=body surface area; DLQI=Dermatology Life Quality Index; EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; POEM=Patient-Oriented Eczema Measure; PP-NRS=Peak Pruritus Numerical Rating Scale; SCORAD=SCORing Atopic Dermatitis.
Prescribing information:
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 200 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 100 mg film-coated tablets.
Cibinqo (abrocitinib) Prescribing Information (Great Britain) – 50 mg film-coated tablets.

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.Bieber T, et al. N Eng J Med 2021;384:1101–1112.Simpson E, et al. Lancet 2020;396:P255–266.Silverberg J, et al. JAMA Dermatol 2021;156(8):863–873.Blauvelt A, et al. JAAD 2021; doi.org/10/1016/j.jaad.2021.05.075.Eichenfield L, et al. JAMA Dermatol 2021; doi: 10.1001/jamadermatol.2021.2830.ClinicalTrials.gov. NCT03422822. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03422822.Hanifin J, et al. Exp Dermatol 2001;10:11–18.Simpson E, et al. J Am Acad Dermatol 2020;83:839–846.Yosipovitch G, et al. Br J Dermatol ​​​​​​​2019;181:761769.
PP-CIB-GBR-0061. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

JADE clinical trial programme

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​